Bergeron C, Shatz P, Margolese R, Major P, Ferenczy A
Department of Pathology, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.
Anal Quant Cytol Histol. 1989 Feb;11(1):33-42.
Monoclonal antibodies B72.3 and MA5 were tested by the avidin-biotin immunoperoxidase method in histologic sections of 38 benign, 22 precancerous and 22 cancerous breast lesions, as well as in fine needle aspiration (FNA) smears and cell blocks of 25 breast carcinomas. Neither B72.3 nor MA5 was specific for breast cancer cells: both also reacted with cells from benign and precancerous conditions. B72.3 as a "detector" of malignant cells or their precursors was superior to MA5, however: it was not reactive to cells in most benign breast lesions (mammary duct ectasia, fibroadenoma and ductal hyperplasia, with and without atypia). Cancerous cells had heterogeneous immunostaining with B72.3, which may lead to false-negative results in relatively hypocellular FNA samples. FNA samples prepared as both smears and cell blocks provided the most abundant cellular samples and the lowest false-negative immunostaining reaction of cancerous cells with B72.3.
采用抗生物素蛋白-生物素免疫过氧化物酶法,在38例乳腺良性病变、22例癌前病变和22例癌性病变的组织切片,以及25例乳腺癌的细针穿刺(FNA)涂片和细胞块中,对单克隆抗体B72.3和MA5进行了检测。B72.3和MA5对乳腺癌细胞均无特异性:二者也与良性和癌前病变的细胞发生反应。然而,B72.3作为恶性细胞或其前体细胞的“检测剂”优于MA5:它对大多数乳腺良性病变(乳腺导管扩张症、纤维腺瘤和导管增生,无论有无异型性)的细胞无反应。癌细胞对B72.3有不同的免疫染色,这可能导致在细胞相对较少的FNA样本中出现假阴性结果。制成涂片和细胞块的FNA样本提供了最丰富的细胞样本,且癌细胞与B72.3的假阴性免疫染色反应最低。